Page last updated: 2024-12-08
casuarinin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
casuarinin: a hydrolyzable tannin from the bark of Terminalia arjuna (Combretaceae) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Terminalia | genus | A plant genus of the family COMBRETACEAE. Members contain arjunin, an ellagitannin (TANNINS).[MeSH] | Combretaceae | A plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mostly trees and shrubs growing in warm areas.[MeSH] |
Terminalia arjuna | species | [no description available] | Combretaceae | A plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mostly trees and shrubs growing in warm areas.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 442673 |
CHEMBL ID | 4168974 |
CHEBI ID | 3462 |
MeSH ID | M0447494 |
Synonyms (7)
Synonym |
---|
79786-01-9 |
casuarinin |
CHEBI:3462 |
DTXSID101000731 |
CHEMBL4168974 |
[(10r,11r)-10-[(14r,15s,19s)-2,3,4,7,8,9,19-heptahydroxy-12,17-dioxo-13,16-dioxatetracyclo[13.3.1.05,18.06,11]nonadeca-1,3,5(18),6,8,10-hexaen-14-yl]-3,4,5,17,18,19-hexahydroxy-8,14-dioxo-9,13-dioxatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-11 |
GLXC-25596 |
Research Excerpts
Overview
Casuarinin is a naturally occurring tannin. It is isolated from the leaves of Hippophae rhamnoides.
Excerpt | Reference | Relevance |
---|---|---|
"Casuarinin is a stachyurin stereoisomer." | ( Divergent Synthesis of Stachyurin and Casuarinin Focusing on C-Glycosidic Bond Reactivity. Ishigami, K; Katsuta, R; Kusuki, R; Murakami, K; Wakamori, S, 2023) | 1.9 |
"Casuarinin is a naturally occurring tannin that is isolated from the leaves of Hippophae rhamnoides. " | ( Casuarinin suppresses TARC/CCL17 and MDC/CCL22 production via blockade of NF-κB and STAT1 activation in HaCaT cells. Bae, YS; Choi, SY; Goh, AR; Ju, SM; Kwon, DJ; Park, J; Youn, GS, 2012) | 3.26 |
Effects
Excerpt | Reference | Relevance |
---|---|---|
"Casuarinin has been shown to be an antioxidant in acellular experiments. " | ( Casuarinin protects cultured MDCK cells from hydrogen peroxide-induced oxidative stress and DNA oxidative damage. Chang-Chien, YW; Chen, CH; Chen, YC; Kuo, TC; Lin, CC; Liu, TZ; Lu, FJ, 2004) | 3.21 |
Treatment
Excerpt | Reference | Relevance |
---|---|---|
"Pretreatment with casuarinin inhibited TNF-α-induced protein and mRNA expression of ICAM-1 and subsequent monocyte adhesiveness in HaCaT cells." | ( Casuarinin suppresses TNF-α-induced ICAM-1 expression via blockade of NF-κB activation in HaCaT cells. Bae, YS; Choi, SY; Goh, AR; Ju, SM; Kwon, DJ; Park, J, 2011) | 2.14 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
tannin | Any of a group of astringent polyphenolic vegetable principles or compounds, chiefly complex glucosides of catechol and pyrogallol. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (1)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1503232 | Antibacterial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of green pigment formation | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10 | Structures and Antibacterial Properties of Isorugosins H-J, Oligomeric Ellagitannins from Liquidambar formosana with Characteristic Bridging Groups between Sugar Moieties. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (19)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (21.05) | 29.6817 |
2010's | 9 (47.37) | 24.3611 |
2020's | 6 (31.58) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 27.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.12) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (95.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |